ResearchMoz

Liver Cancer Therapeutics Market to 2018 - Nexavar, the Only Approved Targeted Therapy for Advanced Disease, Continues to Dominate as Other Late Stage Trials Fail

GBI Research
Published Date » 2012-12-31
No. Of Pages » 72
     
  Liver Cancer Therapeutics Market to 2018 - Nexavar, the Only Approved Targeted Therapy for Advanced Disease, Continues to Dominate as Other Late Stage Trials Fail  
     
  Summary  
   
 Leading business intelligence provider, GBI Research, has released its latest research report, entitled: “Liver Cancer Therapeutics Market to 2018 - Nexavar, the Only Approved Targeted Therapy for Advanced Disease, Continues to Dominate as Other Late Stage Trials Fail”. The report provides insights into the liver cancer therapeutics market in the US, the top five European countries (the UK, Germany, France, Italy and Spain) and Japan, with market forecasts until 2018. It provides in-depth analysis of the major marketed products, as well as insights into the liver cancer...
Table of Contents

1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 7
1.2 List of Figures 8

2 Liver Cancer Therapeutics Market to 2018 - Introduction 9

3 Liver Cancer Therapeutics Market to 2018 - Overview 10
3.1 Introduction 10
3.1.1 Benign Tumor 10
3.1.2 Primary Liver Cancer 10
3.1.3 Secondary Liver Cancer 10
3.2 Symptoms 11
3.3 Diagnosis 11
3.3.1 Laboratory Tests 11
3.3.2 Imaging Tests 11
3.3.3 Others 12
3.4 Treatment Options 12
3.4.1 Surgery 13
3.4.2 Non-surgical 13
3.4.3 General Treatment Algorithm 15
3.4.4 Treatment by Stage 16
3.4.5 New Technologies in Treatment 18

4 Liver Cancer Therapeutics Market to 2018 - Market Characterization and Forecasts 19
4.1 Revenue 19
4.2 Annual Cost of Therapy 22
4.3 Marketed Products 23
4.3.1 Nexavar 23
4.3.2 Miripla 25
4.4 Treatment Usage Pattern 27
4.4.1 Prevalence Population 28
4.4.2 Diagnosed Population 28
4.4.3 Prescription Population 28
4.5 Drivers and Barriers of Liver Cancer Therapeutics Market 28
4.5.1 Drivers 28
4.5.2 Barriers 29

5 Liver Cancer Therapeutics Market to 2018 - Geographical Landscape 30
5.1 US 30
5.1.1 Introduction 30
5.1.2 Revenue 30
5.1.3 Cost of Therapy 32
5.1.4 Treatment Usage Pattern 33
5.2 Top Five European Countries 34
5.2.1 Introduction 34
5.2.2 Revenue 34
5.2.3 Cost of Therapy 36
5.2.4 Treatment Usage Pattern 37
5.3 Japan 38
5.3.1 Introduction 38
5.3.2 Revenue 38
5.3.3 Cost of Therapy 39
5.3.4 Treatment Usage Pattern 40

6 Liver Cancer Therapeutics Market to 2018 - Pipeline Analysis 41
6.1 Introduction 41
6.2 R&D Product Pipeline by Stage of Development 43
6.2.1 Phase III 43
6.2.2 Phase II/III 44
6.2.3 Phase II 44
6.2.4 Phase I/II 45
6.2.5 Phase I 46
6.2.6 Pre-Clinical 47
6.2.7 Discovery 47
6.3 Profiles of Promising Molecules 48
6.3.1 PrevOnco 48
6.3.2 Ramucirumab 48
6.3.3 ThermoDox 49
6.3.4 Afinitor 50

7 Liver Cancer Therapeutics Market to 2018 - Competitive Landscape 51
7.1 Bayer 51
7.2 Dainippon Sumitomo Pharma 52

8 Liver Cancer Therapeutics Market to 2018 - Strategic Consolidations 53
8.1 Introduction 53
8.2 Deals by Geography 54
8.3 Deals by Year 55
8.4 Mergers and Acquisition Deals 56
8.4.1 Overview 56
8.4.2 Profiles of Major M&A Deals 57
8.5 Licensing Agreements 58
8.5.1 Overview 58
8.5.2 Profiles of Major Licensing Agreements 60
8.6 Co-Development Agreements 62
8.6.1 Overview 62
8.6.2 Profiles of Major Co-Development Agreements 63

9 Liver Cancer Therapeutics Market to 2018 - Appendix 64
9.1 Market Definitions 64
9.2 Abbreviations 64
9.3 Bibliography 66
9.4 Research Methodology 67
9.4.1 Coverage 67
9.4.2 Secondary Research 68
9.4.3 Primary Research 68
9.5 Therapeutic Landscape 69
9.5.2 Market Size by Geography 70
9.6 Geographical Landscape 71
9.7 Pipeline Analysis 71
9.8 Competitive Landscape 72
9.8.1 Expert Panel Validation 72
9.9 Contact Us 72
9.10 Disclaimer 72

List of Tables


Table 1: Liver Cancer Therapeutics Market, Top Seven Markets, Revenue ($m), 2004-2011 19
Table 2: Liver Cancer Therapeutics Market, Top Seven Markets, Revenue Forecasts ($m), 2011-2018 19
Table 3: Liver Cancer Therapeutics Market, Top Seven Markets, Revenue by Geography ($m), 2004-2011 20
Table 4: Liver Cancer Therapeutics Market, Top Seven Markets, Revenue Forecasts by Geography ($m), 2011-2018 21
Table 5: Liver Cancer Therapeutics Market, Top Seven Markets, Annual Cost of Therapy ($), 2004-2011 22
Table 6: Liver Cancer Therapeutics Market, Top Seven Markets, Annual Cost of Therapy ($), 2011-2018 22
Table 7: Liver Cancer Therapeutics Market to 2018, Nexavar, Clinical Trial Results 23
Table 8: Liver Cancer Therapeutics Market, Nexavar, Adverse Reactions Reported in Clinical Trial 24
Table 9: Liver Cancer Therapeutics Market, Nexavar, Approval History 25
Table 10: Liver Cancer Therapeutics Market, Top Seven Markets, Treatment Usage Pattern (‘000), 2004-2011 27
Table 11: Liver Cancer Therapeutics Market, Top Seven Markets, Treatment Usage Pattern (‘000), 2011-2018 27
Table 12: Liver Cancer Therapeutics Market, US, Revenue ($m), 2004-2011 30
Table 13: Liver Cancer Therapeutics Market, US, Revenue Forecasts ($m), 2011-2018 31
Table 14: Liver Cancer Therapeutics Market, US, Annual Cost of Therapy ($), 2004-2011 32
Table 15: Liver Cancer Therapeutics Market, US, Annual Cost of Therapy ($), 2011-2018 32
Table 16: Liver Cancer Therapeutics Market, US, Treatment Usage Pattern (‘000), 2004-2011 33
Table 17: Liver Cancer Therapeutics Market, US, Treatment Usage Pattern (‘000), 2011-2018 33
Table 18: Liver Cancer Therapeutics Market, Top Five European Countries, Revenue ($m), 2004-2011 35
Table 19: Liver Cancer Therapeutics Market, Top Five European Countries, Revenue Forecast ($m), 2011-2018 35
Table 20: Liver Cancer Therapeutics Market to 2018, Top Five European Countries, Annual Cost of Therapy ($), 2004-2011 36
Table 21: Liver Cancer Therapeutics Market to 2018, Top Five European Countries, Annual Cost of Therapy ($), 2011-2018 36
Table 22: Liver Cancer Therapeutics Market, Top Five European Countries, Treatment Usage Pattern (‘000), 2004-2011 37
Table 23: Liver Cancer Therapeutics Market, Top Five European Countries, Treatment Usage Pattern (‘000), 2011-2018 37
Table 24: Liver Cancer Therapeutics Market, Japan, Revenue ($m), 2004-2011 38
Table 25: Liver Cancer Therapeutics Market, Japan, Revenue Forecast ($m), 2011-2018 39
Table 26: Liver Cancer Therapeutics Market, Japan, Annual Cost of Therapy ($), 2004-2011 39
Table 27: Liver Cancer Therapeutics Market, Japan, Annual Cost of Therapy ($), 2011-2018 39
Table 28: Liver Cancer Therapeutics Market, Japan, Treatment Usage Pattern (‘000), 2004-2011 40
Table 29: Liver Cancer Therapeutics Market, Japan, Treatment Usage Pattern (‘000), 2011-2018 40
Table 30: Liver Cancer Therapeutics Market, Global, Pipeline Products, by Stage of Development, 2012 42
Table 31: Liver Cancer Therapeutics Market, Global, Phase III Pipeline 43
Table 32: Liver Cancer Therapeutics Market, Global, Phase II/III Pipeline 44
Table 33: Liver Cancer Therapeutics Market, Global, Phase II Pipeline 44
Table 34: Liver Cancer Therapeutics Market, Global, Phase I/II Pipeline 45
Table 35: Liver Cancer Therapeutics Market, Global, Phase I Pipeline 46
Table 36: Liver Cancer Therapeutics Market, Global, Preclinical, 2012 47
Table 37: Liver Cancer Therapeutics Market, Global, Discovery, 2012 47
Table 38: Liver Cancer Therapeutics Market, Global, Bayer AG, Pharmaceutical Brands, 2012 51
Table 39: Liver Cancer Therapeutics Market, Global, Dainippon Sumitomo Pharma, Pharmaceutical Brands, 2012 52
Table 40: Liver Cancer Therapeutics Market, Global, Deals by Type of Agreement, 2007-2012 53
Table 41: Liver Cancer Therapeutics Market, Global, Deals by Geography, 2007-2012 54
Table 42: Liver Cancer Therapeutics Market, Global, Deals by Year, 2007-2012 55
Table 43: Liver Cancer Therapeutics Market, Global, Major M&A Deals, 2007-2012 56
Table 44: Liver Cancer Therapeutics Market, Global, Major Licensing Agreement Deals, 2007-2012 58
Table 45: Liver Cancer Therapeutics Market, Global, Major Co-Development Deals, 2007-2012 62

List of Figures


Figure 1: Liver Cancer Therapeutics Market, Global, Hepatocellular Carcinoma, Treatment Options, 2012 12
Figure 2: Liver Cancer Therapeutics Market, Global, Hepatocellular Carcinoma, General Treatment Algorithm 15
Figure 3: Liver Cancer Therapeutics Market, Global, Hepatocellular Carcinoma, Stage I and II, Treatment Algorithm 16
Figure 4: Liver Cancer Therapeutics Market, Global, Hepatocellular Carcinoma, Stage III and IV, Treatment Algorithm 17
Figure 5: Liver Cancer Therapeutics Market, Top Seven Markets, Revenue Forecasts ($m), 2004-2018 19
Figure 6: Liver Cancer Therapeutics Market, Top Seven Markets, Revenue Forecasts by Geography ($m), 2004-2018 20
Figure 7: Liver Cancer Therapeutics Market, Top Seven Markets, Annual Cost of Therapy ($), 2004-2018 22
Figure 8: Liver Cancer Therapeutics Market, Top Seven Markets, Treatment Usage Pattern (‘000), 2004-2018 27
Figure 9: Liver Cancer Therapeutics Market, Top Seven Markets, Drivers and Barriers, 2012 29
Figure 10: Liver Cancer Therapeutics Market, US, Revenue Forecasts ($m), 2004-2018 30
Figure 11: Liver Cancer Therapeutics Market, US, Annual Cost of Therapy ($), 2004-2018 32
Figure 12: Liver Cancer Therapeutics Market, US, Treatment Usage Pattern (‘000), 2004-2018 33
Figure 13: Liver Cancer Therapeutics Market, Top Five European Countries, Revenue Forecast ($m), 2004-2018 34
Figure 14: Liver Cancer Therapeutics Market, Top Five European Countries, Market Revenue ($m), 2004-2018 35
Figure 15: Liver Cancer Therapeutics Market, Top Five European Countries, Annual Cost of Therapy ($), 2004-2018 36
Figure 16: Liver Cancer Therapeutics Market, Top Five European Countries, Treatment Usage Pattern (‘000), 2004-2018 37
Figure 17: Liver Cancer Therapeutics Market, Japan, Revenue Forecast ($m), 2004-2018 38
Figure 18: Liver Cancer Therapeutics Market, Japan, Annual Cost of Therapy ($), 2004-2018 39
Figure 19: Liver Cancer Therapeutics Market, Japan, Treatment Usage Pattern (‘000), 2004-2018 40
Figure 20: Liver Cancer Therapeutics Market, Global, Pipeline Products, by Stage of Development, 2012 41
Figure 21: Liver Cancer Therapeutics Market, Global, Deals by Type of Agreement, 2007-2012 53
Figure 22: Liver Cancer Therapeutics Market, Global, Deals by Geography, 2007-2012 54
Figure 23: Liver Cancer Therapeutics Market, Global, Deals by Year, 2007-2012 55
Figure 24: GBI Research Market Forecasting Model 71

Upcoming Reports:

Green Solvent and Bio-Solvents Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019
By - Transparency Market Research
A solvent is generally any liquid (could be solid or gas also), which has the capacity to dissolve a substance (solute) in it resulting in the formation of a solution. The solvent market has seen a rise in the last few years, which has caused high levels of toxic emission in the atmosphere. Traditional solvents emit VOC (volatile organic compounds) and are being increasingly used in paints, aerosol, and in other similar industries. With environmental regulations to lower the emissions of VOC and bio-solvents or green-solvents have seen a growth in the past few years. The...
Chromatography Accessories and Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020
By - Transparency Market Research
Chromatography is one of the most important separation processes for biomolecules. It is the ability to separate molecules using partitioning characteristics of molecule to remain in a stationary phase versus a mobile phase. Once a molecule is separated from the mixture, it can be isolated and quantified. Chromatographic separation consists of two major components mobile phase and stationary phase. The various mixture constituents travel at different speeds, causing them to separate and this separation is based on differential partitioning between the stationary and mobile phases. The...
Dental Implants Market- Global Industry Size, Market Share, Trends, Analysis And Forecasts 2012-2018
By - Transparency Market Research
Increasing awareness for dental implants is one of the major factors driving global dental implants market. Implant techniques are widely accepted and executed by dentists worldwide. Continuous growth in the global market has resulted in an increasing demand for improved oral aesthetics, which has led to an increased number of dental practitioners performing dental implant surgeries. Some other factors driving the market are technological improvements, brand name recognition, and cost efficiency relative to alternative treatments.  This research report analyzes the dental...

Research Assistance

We will be happy to help you find what you need.
Please call us or write us:

866-997-4948 (Us-Canada Toll Free)
Tel: +1-518-618-1030
Email: sales@researchmoz.us
Select License type:

Share this report

Related News

Private Schools Have Higher Male Teaching Staff Than State Schools: Report
Oct 22, 2014  
Private and state education has always been a matter of debate across the UK. A recent study has shown that when it comes to teaching employment options, the difference between state-run and private education in terms of gender balance is absolutely clear.  A report by the Independent Schools Council (ISC) shows that while women dominate both the education medium, the number of...
Abbots First Australian Renewable Energy Deal Rejected
Oct 22, 2014  
The Abbot government’s initial deal for a renewable energy plan has been immediately rejected by the clean energy industry and Labor. The negotiations are about a bipartisan agreement regarding the future of the Australian renewable energy target. The Labor party rejected the first plan as being a job-killer before it was even announced. The plan, they said, would protect solar...
Chemical Production in Europe Flatlines in First Seven Months of 2014
Oct 21, 2014  
The recently published report by European Chemical Industry Council (Cefic) shows overall chemical production in Europe has flatlined in first seven months of this year. Though the initial four months showed a positive trend, the production volumes dropped in July 2014 and in the following months as well. The contraction in output in the three consecutive months has nullified the upward trend...
Actavis to Compete for Omega Pharma
Oct 20, 2014  
Actavic Plc has declared that it will become one of the bidders for the Omega Pharma NV deal, as the United States based drug maker keeps searching for more takeovers. Actavis will be competing against Boehringer Ingelheim GmbH, Sanofi and Perrigi Co. for Omega Pharma. Actavis places themselves as a potential suitor along with quarry in a multitude of potential pharma combinations....
Sale of iPhone Fuels UKs s
Oct 20, 2014  
With the sale of Apple Inc.’s latest smartphone, consumer expenditure on electronics has registered a three-year high this September. The new iPhone 6 and iPhone 6 Plus were launched in the U.K. on September 19 and buyers from across the country raced to purchase the newest smartphone. Both these smartphones are so far the fastest selling Apple products with a sale of over 10 million...